

Novo Nordisk invests RMB 800 M to expand manufacturing plant in China

14 July 2025 | News

The expanded laboratory plant will meet the future testing requirements for pharmaceutical production



Novo Nordisk has signed a Memorandum of Understanding (MoU) with TEDA Administrative Commission, agreeing to invest approximately RMB 800 million in the expansion of quality testing laboratories at its Tianjin manufacturing plant.

With a total construction area of approximately 18,000 square meters, the project will build chemical, microbiological, and biological laboratories, which is scheduled to be completed by the end of 2026.

Once operational, the expanded laboratory plant will meet the future testing requirements for pharmaceutical production at Novo Nordisk's Tianjin plant, further advancing the development of the biopharmaceutical industry in Tianjin TEDA (Tianjin Economic-Technological Development Area).

Novo Nordisk is a leading global biopharmaceutical company headquartered in Denmark, providing products and services to approximately 170 countries and regions worldwide. In 1994, Novo Nordisk established its Tianjin manufacturing plant in TEDA, marking its first step in starting business in China. Today, the Tianjin plant has grown into one of Novo Nordisk's strategic production bases, fully committed to green and sustainable practices by utilizing 100% renewable wind energy.

In recent years, Novo Nordisk has continuously increased its investments to accelerate development in Tianjin. In 2023, the company invested RMB 1.18 billion to expand its finished products workshop and introduced a prefilled injection pen production line. In 2024, it invested approximately RMB 4 billion in a sterile formulation expansion project. This year, it

invested around RMB 800 million in laboratory expansion. So far, Novo Nordisk's cumulative investment in TEDA has exceeded RMB 10 billion, fully demonstrating its strong confidence in long-term development there.